Gland Pharma: Should investors consider buying this pharma stock after losing 68% of its value?

Axis Securities remains optimistic about the company's growth prospects, citing the positive performance of injectable companies in the US market. 

Nifty Pharma up 6% in less than 2 months. Why are pharma stocks rising? Can they sustain the momentum?

Some of the pharma stocks, such as Aurobindo Pharma, Glenmark Pharma, Divi's Laboratories, Dr. Reddy’s Labs, Abbott India and Zydus Lifesciences have risen in double digits since March.

Nomura Group expects pharma firms to report decent earnings; picks Zydus Lifesciences, Alkem Lab, Medplus

<ul><li>In the brokerage's pharma coverage universe as a whole, it anticipates revenue growth between 3% and 13% quarterly (q-o-q) and annually (y-o-y).</li></ul>

Zydus Lifesciences hits new 52-week high; gains 6.2% in 3 days

The stock lost 29.35 percent of its value between July and December of last year, gradually declining from ₹570.45 to ₹403. But in 2023, it got off to a strong start, generating a return of almost 8 percent so far in the current month, with the majority of gains occurring in the last 3 trading days at 6.18 percent.

Pharma and healthcare stocks close higher as COVID threat re-emerges after infections rise in China

<ul><li>IOL Chemicals &amp; Pharmaceuticals Ltd, Ajanta Pharma Ltd, and Sun Pharma Advanced Research Company Ltd gained 6-7 percent in today's session.</li></ul>

Julius Baer downgrades Alkem Labs to ‘hold’ on soft Q2 results; stock down 15% this year

Julius Baer (JB) has downgraded Alkem Labs to 'hold' from 'buy' on the back of soft September quarter (Q2FY23) results. It has a target price of ₹3,400, indicating an upside of 10 percent from the current market price.

Brokerages bullish on Glenmark Pharma despite muted Q2 earnings. Here's why

<ul><li>Glenmark Pharma has corrected about 20.44 percent and Nifty Pharma has lost around 9 percent in 2022 so far.</li></ul>

Brokerages cautious on pharma sector post Q2FY23 numbers; here are their top picks

Nirmal Bang Institutional Equities underscored that the Q2FY23 performance by its pharma universe was mainly driven by the 'Revlimid' launch in the US market.

Nifty Pharma is down 10% in one year; Can it be a 'contra' bet from hereon? Here's what 4 analysts say

<ul><li>It is early to say that pharma stocks are now on the cusp of a revival. However, they can do selectively well from here, analysts believe.</li></ul>

Earnings revision: Retail, BFSI sees upgrades, while pharma stocks sustains downgrades

Based on the earnings revisions, we compile list of the top 10 stocks on either side of the spectrum

Top Pharma Stocks News

markets

Gland Pharma: Should investors consider buying this pharma stock after losing 68% of its value?

markets

markets

markets